Two founder mutations in the alpha-tropomyosin and the cardiac myosin-binding protein C genes are common causes of hypertrophic cardiomyopathy in the Finnish population

Pertti Jääskeläinen(University of Eastern Finland), Mikko Pietilä(Fondazione Toscana Gabriele Monasterio), Paavo Uusimaa(Oulu University Hospital), Helena Kervinen(North Karelia Central Hospital), Erkki Ilveskoski(Tampere University Hospital), Markku S. Nieminen(Cornell University), Johanna Kuusisto(University of Eastern Finland), Mari Niemi(Wellcome Sanger Institute), Markku Laakso(Cleveland Clinic), M Kotila(Seinäjoki University of Applied Sciences), Liisa Hämäläinen(Vaasa Central Hospital), John Melin(Central Finland Health Care District), Matti Huttunen, Juha Mustonen(Kajaani University of Applied Sciences), Jukka Juvonen(Kajaani University of Applied Sciences), Tiina Heliö(Helsinki University Hospital), Maija Kaartinen(Savonlinna Central Hospital), Katriina Aalto‐Setälä(Tampere University)
Annals of Medicine
April 2, 2012
10.3109/07853890.2012.671534
Cited by 45

Related Papers

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
|The Lancet|2002|5.4k
FinnGen provides genetic insights from a well-phenotyped isolated population
|Nature|2023|4.2k
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
|The Lancet|2003|3.8k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2013|3.4k